Natelson B H, Ye N, Moul D E, Jenkins F J, Oren D A, Tapp W N, Cheng Y C
Chronic Fatigue Syndrome Center, UMDNJ-New Jersey Medical School, Newark.
J Med Virol. 1994 Jan;42(1):42-6. doi: 10.1002/jmv.1890420109.
Forty-one patients with chronic fatigue syndrome (CFS), 76 healthy controls matched with the patient group for age range, sex, race, and socioeconomic class, and 22 symptomatic patients with seasonal affective disorder (SAD) had serum sampled for antibodies against 2 Epstein-Barr virus (EBV) replicating enzymes. Abnormal titers of antibodies were found twice as often in CFS patients as controls (34.1% vs. 17.1%), with SAD patients having an intermediate frequency (27.3%). Stratifying for disease severity sharpened the differences considerably, with the sicker CFS and SAD patients having 52% and 50% abnormal tests, respectively; more mildly afflicted CFS and SAD patients had a frequency of abnormal tests in the normal range. Antibodies to EBV DNA polymerase (DNAP) were the more sensitive of the two tests in that they were positive in all cases but one. These findings suggest that antibodies against EBV DNAP may be a useful marker in delineating a subset of patients with severe fatiguing illness for appropriate treatment trials and for monitoring their outcomes.
41名慢性疲劳综合征(CFS)患者、76名在年龄范围、性别、种族和社会经济阶层方面与患者组相匹配的健康对照者,以及22名有季节性情感障碍(SAD)症状的患者,均采集了血清以检测针对2种爱泼斯坦-巴尔病毒(EBV)复制酶的抗体。CFS患者中抗体滴度异常的发生率是对照组的两倍(34.1%对17.1%),SAD患者的发生率处于中间水平(27.3%)。按疾病严重程度分层后,差异显著增大,病情较重的CFS和SAD患者的检测异常率分别为52%和50%;病情较轻的CFS和SAD患者的检测异常率在正常范围内。EBV DNA聚合酶(DNAP)抗体是两种检测中更敏感的一种,因为除1例之外,所有病例中该抗体检测均呈阳性。这些发现表明,针对EBV DNAP的抗体可能是一种有用的标志物,可用于确定患有严重疲劳疾病的患者亚组,以便进行适当的治疗试验并监测其治疗结果。